BiotechTube

methylphenidate HCl ERCT + Placebo

ApprovedWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Attention Deficit Hyperactivity Disorder (ADHD)

Conditions

Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder

Trial Timeline

Oct 31, 2018 → Oct 12, 2021

NCT ID
NCT03580005

About methylphenidate HCl ERCT + Placebo

methylphenidate HCl ERCT + Placebo is a approved stage product being developed by Pfizer for Attention Deficit Hyperactivity Disorder (ADHD). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03580005. Target conditions include Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder.

What happened to similar drugs?

11 of 20 similar drugs in Attention Deficit Hyperactivity Disorder (ADHD) were approved

Approved (11) Terminated (1) Active (9)
✅atomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Atomoxetine HydrochlorideEli LillyApproved
🔄AtomoxetineEli LillyPhase 3
✅AtomoxetineEli LillyApproved
✅Atomoxetine hydrochloride + PlaceboEli LillyApproved
🔄CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03580005ApprovedWithdrawn

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder (ADHD)

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
Atomoxetine + PlaceboEli LillyPhase 2/3
38
AtomoxetineEli LillyApproved
35
Atomoxetine HydrochlorideEli LillyApproved
43
AtomoxetineEli LillyPhase 3
40
AtomoxetineEli LillyApproved
43
Atomoxetine hydrochloride + PlaceboEli LillyApproved
43
CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3
40
Donepezil hydrochloride + PlaceboEisaiPhase 3
40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)Eli LillyPhase 2/3
38
Atomoxetine + PlaceboEli LillyApproved
43
AtomoxetineEli LillyApproved
43
AtomoxetineEli LillyPre-clinical
26
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine hydrochlorideEli LillyPhase 3
40
Atomoxetine Hydrochloride + PlaceboEli LillyApproved
43
atomoxetineEli LillyPhase 3
40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/dayEli LillyPhase 3
40
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine HydrochlorideEli LillyPhase 3
40